Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Design Therapeutics (DSGN) Total Current Liabilities (2020 - 2026)

Design Therapeutics' Total Current Liabilities history spans 2 years, with the latest figure at $5.3 million for Q4 2021.

  • On a quarterly basis, Total Current Liabilities rose 126.74% to $5.3 million in Q4 2021 year-over-year; TTM through Dec 2021 was $5.3 million, a 126.74% increase, with the full-year FY2021 number at $5.3 million, up 126.74% from a year prior.
  • Total Current Liabilities hit $5.3 million in Q4 2021 for Design Therapeutics, down from $5.5 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for DSGN hit a ceiling of $5.5 million in Q3 2021 and a floor of $2.3 million in Q4 2020.